Feasibility Assessment of a Patients Follow-up Visit Receiving Trastuzumab Subcutaneous by Advanced Practice Nurse

NCT ID: NCT02686918

Last Updated: 2016-02-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-29

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main of this study is to assess the feasibility of a patients follow-up visit receiving trastuzumab subcutaneous by Advanced Practice Nurse.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

consultation by Advanced Practice Nurse.

During consultations, patients will be seen successively by Advanced Practice Nurse and referent oncologist.

Group Type EXPERIMENTAL

Advanced Practice Nurse consultation

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Advanced Practice Nurse consultation

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient care at the Cancer Institute Lucien Neuwirth
* Patient aged over 18 years
* Patient with breast cancer overexpressing HER2 adjuvant
* Patient having finished their chemotherapy treatment with IV followed the oncologist day hospital
* Patient under Trastzumab subcutaneously
* Patient affiliated or entitled to a social security scheme (mandatory requirement for all studies)

Exclusion Criteria

* Refusal to participate, most patient protected under guardianship.
* Patient in inability to understand the course of the study
* Patient with documented history of cognitive or psychiatric disorders.
* Patients pregnant or lactating
* Patients under guardianship or curatorship
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut de Cancérologie de la Loire

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mathieu ORIOL, MD

Role: CONTACT

04 77 91 70 71

Cécile MIGALA, IPA

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.